Tracking virus outbreaks in the twenty-first century

Nathan D. Grubaugh¹,², Jason T. Ladner ³*, Philippe Lemey⁴, Oliver G. Pybus⁵, Andrew Rambaut ⁶,⁷*, Edward C. Holmes ⁸* and Kristian G. Andersen ⁹,¹

Emerging viruses have the potential to impose substantial mortality, morbidity and economic burdens on human populations. Tracking the spread of infectious diseases to assist in their control has traditionally relied on the analysis of case data gathered as the outbreak proceeds. Here, we describe how many of the key questions in infectious disease epidemiology, from the initial detection and characterization of outbreak viruses, to transmission chain tracking and outbreak mapping, can now be much more accurately addressed using recent advances in virus sequencing and phylogenetics. We highlight the utility of this approach with the hypothetical outbreak of an unknown pathogen, ‘Disease X’, suggested by the World Health Organization to be a potential cause of a future major epidemic. We also outline the requirements and challenges, including the need for flexible platforms that generate sequence data in real-time, and for these data to be shared as widely and openly as possible.

Emerging infectious diseases present one of the greatest public health challenges of the twenty-first century. Among these are zoonotic viruses that originate from reservoir species, often mammals, and jump to humans to cause disease syndromes of varying form and severity. An emerging virus, depending on its ability to transmit among humans, can lead to individual or a few sporadic cases, resulting in a localized outbreak that requires public health intervention or, in the worst scenarios, can develop into a large epidemic or global pandemic. Such emergence events over the past two decades are numerous and varied. They include viruses not previously encountered, such as the SARS and MERS coronaviruses ¹⁻⁴, and familiar foes that have reappeared to cause outbreaks, such as swine- and avian-origin influenza ⁵⁻⁶, and Ebola ⁷ and Zika ⁸ viruses. Although many outbreaks end naturally or are controlled quickly, questions remain over how best to scientifically respond to these events.

The broad-scale factors responsible for viral emergence have been well documented and include human population growth, increased frequency and reach of travel, changing patterns of land use, changing diets, wars and social upheaval and climate change ⁹⁻¹⁰. These factors increase interactions between humans and reservoir hosts, facilitating exposure to zoonotic viruses and spillover infections in people, and allow emerging viruses to spread more easily through human populations. The interactions between virus genetics, ecology and the host factors that determine virus emergence are so complex that it is impossible to predict what virus will cause the next epidemic, making it essential that our response is scientifically informed, robust and efficient ¹¹.

The emergence of virus outbreaks generates a set of common questions, whose answers are central to disease mitigation and control (Table 1), and which at times can only be answered by sequencing of viral genomes. These include what is the virus, is it novel, or does it represent the re-emergence of a known pathogen; what is its mode of transmission; where does the emerging virus come from (in particular, what is its reservoir host and/or geographic source); what ecological factors underpin its emergence; how many introductions into humans have there been; what is the timing of these introduction events, and was there a period of undetected transmission before the first reported case; during flare-ups and future outbreaks, how are they connected to previous events; and what is the nature of virus evolution and is there evidence for local adaptation? In the past, many of these of questions were addressed using case data alone cannot inform public health management with the level of precision necessary for all targeted interventions. Recent advances in virus genome sequencing and phylogenetic analyses, however, mean that we are now in a position to answer such questions with molecular precision, and open new areas of investigations not previously possible based on epidemiological data alone (Table 1).

Virus genomics have been used to investigate infectious disease outbreaks for several decades. This is possible because viruses, particularly those with RNA genomes, generate genetic variation on the same timescale of virus transmission, through a combination of high rates of mutation and replication ¹¹⁻¹³. Consequently, it is possible to infer epidemiological and emergence dynamics from virus genomes sampled and sequenced over short epidemic timescales. We term the science of using genomics and associated analyses ‘genomic epidemiology’.

Initially, genomic approaches relied on indirect methods (for example, restriction fragment length polymorphisms ¹⁴⁻¹⁵) to infer...
from initial virus detection to understanding the factors contributing towards global spread (Box 1). We will show how genomic epidemiology can be used to track the spread of emerging viruses, where the challenges lie, and establish an agenda for future work. Although we focus on human disease, the genome-based methodologies that we describe can be equally applied to animal and plant infections. Similarly, the increasing ability to rapidly sequence complete genomes of bacterial species means that these technologies offer much to the study of emerging bacterial disease, including those associated with antimicrobial resistance.

### Outbreak detection
Most infectious disease outbreaks start with clinicians noticing unusual patterns. Patients may present with patterns of symptoms that are similar to those of more common diseases, but which, after repeated observation and diagnostic testing, may deviate in scale, seasonality or severity. At this very beginning of an outbreak, the most critical task is therefore to identify a causal pathogen. Historically, virus identification has been performed using molecular tools, such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA), that directly recognize pathogen-derived material (Box 2), or conventional non-molecular techniques, such as microscopy. The advent of untargeted metagenomic sequencing directly from clinical samples, however, means that we are now on the cusp of being able to detect human viruses in a single step, without a priori knowledge of putative causal pathogens (Box 2). The major advantage of sequencing-based approaches is the ability to detect novel viruses—such as the initial appearances of SARS, MERS or Lujo virus—or unexpected ones, as exemplified by Ebola virus during the 2013–2016 epidemic in West Africa.

Once an outbreak has been detected and a causal virus identified, several basic questions can immediately be answered about the virus itself, including: (1) whether it is novel or previously known to infect humans; and (2) if we have the diagnostics, vaccines and therapeutics available to fight it. Importantly, the generation of virus genomics data at this stage will provide deeper insights into these questions by uncovering molecular details not possible with conventional tools. Phylogenetics will also provide an additional level of detail, revealing virus origins, evolutionary characteristics and connections to previous outbreaks in the same region, or to transmissions in other regions. Given high enough relatedness to other members of a virus family with well-defined reservoir hosts (for example, old-world arenaviruses), the sequence identification of novel virus species can also be informative about potential reservoirs.

### First snapshot of an outbreak
Immediately after a viral outbreak has been identified there exists a ‘fog-of-war’. The extent of the outbreak, the timing and nature of its source, and the contribution of human-to-human transmission will be extremely limited, yet these data are critical to designing effective responses. Genomic epidemiology, if applied quickly and comprehensively, holds the potential to answering these questions.

To provide an initial snapshot of an outbreak, it is important to understand the diversity of circulating viruses from as many cases as possible. Virus genetic diversity, measured as the average number of nucleotide differences among viruses in the population, will increase as an outbreak progresses due to the accumulation of genetic changes in virus genomes at each round of viral replication. If this rate of mutational accumulation is relatively constant—that is, it conforms to a ‘molecular clock’ of evolutionary change—then the rate at which it occurs (referred to as the ‘evolutionary rate’) allows us to estimate when the sequenced viruses last shared a common ancestor. Critically, this provides a lower bound on when an outbreak began, and how long the virus had been circulating prior to discovery. If the virus genomes have been sampled over only
Box 1 | Outbreak of Disease X: a hypothetical scenario

In addition to the Ebola, SARS and Zika viruses, the WHO watch-list of viruses that may lead to public health emergencies acknowledged for the first time that the next serious epidemic may be caused by a currently unknown virus—Disease X. Its inclusion emphasizes the need for flexible and deployable platforms to understand and combat disease outbreaks of many varieties. Most likely, Disease X may be a known microorganism believed to cause no or mild human disease, as was the case for Zika virus before its epidemic in the Americas. Disease X could emerge anywhere in the world and, given the mobility of human populations, it could spread to distant and highly populated regions within days or weeks. To illustrate how genomic epidemiology can successfully reveal important aspects of disease emergence and inform epidemic control efforts, we present a hypothetical scenario in which Disease X successfully jumped into humans, established sustained transmission and caused severe disease.

In Miami, Florida (United States), a 22-year-old man sought medical assistance after an influenza-like illness suddenly progressed to a dangerously high fever and laboured breathing. He reported golfing activity at nearby resorts, harbouring clusters of wildlife, including birds. He was admitted into the emergency room and within 3 days died of pneumonia. During this time, 5 other young adults presented with similar symptoms to Miami-area hospitals. Standard molecular diagnostics for commonly suspected pathogens were negative, but immunoglobulin M antibodies collected from each patient were slightly cross-reactive to MERS and SARS coronaviruses. Since the virus could not be conclusively identified with conventional assays, metagenomic sequencing was used to identify Disease X as a novel human virus, most closely related to other coronaviruses in ducks (see figure, panel a). Importantly, due to the relatedness of the novel virus to a family of viruses with well-defined host-ranges, these data led to a hypothesis about its potential origin and reservoir (overwintering migratory birds in the nearby Everglades wetlands) and allowed for the development of virus-specific diagnostics and targeted sequencing approaches.

Within 3 weeks, there were 40 new laboratory-confirmed Disease X cases, including 8 from healthcare workers who contacted the original 6 cases, and 5 total deaths (an 11% apparent case fatality rate). Targeted sequencing from 15 patients and related viruses, including from ducks across Southern Florida, revealed that the human Disease X viruses clustered together on a phylogenetic tree and shared a common ancestor with virus genomes from ducks near Palm Beach, suggesting there was a single zoonotic spillover event and subsequent human-to-human transmission (panel b). A molecular clock phylogenetic analysis further indicated that the common ancestor of the human viruses existed several months ago, suggesting that the first patient identified was not the first case of the outbreak, and highlighting the possibility of many more unreported or asymptomatic cases.

As the outbreak progressed, there was a critical need to understand transmission to help control further spread. Traditional epidemiology, including contact tracing, provided Real-time genomic investigation of Disease X. a, Metagenomic sequencing revealed that Disease X, which could not be identified using standard clinical assays, was a novel virus. b, Targeted sequencing from additional human cases and from related viruses uncovered the likely animal reservoir, the time period that it was introduced into the human population (represented by * in the lower panel), and that subsequent transmission was human-to-human. c, More intensive virus genome sequencing was used to construct detailed transmission chains and identify potential control measures. d, Layering additional climatic (pictured in the lower panel; https://www.climate.gov/maps-data), transportation, geographic, economic and demographic information into a large phylogenetic data set revealed the risk factors that facilitated local and global spread. Images and icons courtesy of S. Knemeyer.
important insights into the risk factors for transmission. Virus genome sequencing was used to infer transmission chains that linked each infected patient (panel c). These analyses revealed that: (1) transmission occurred primarily between individuals that had been in close proximity; and (2) a few individuals infected most of the known cases. In response, an action plan of patient isolation/containment and widespread use of facemasks was implemented to reduce close contact and aerosol transmission.

The Disease X outbreak peaked within a year, resulting in ~2,000 cases in Florida and several imported cases throughout the world. Most of the imported cases did not result in secondary local infections, with the exception of two healthcare workers in New York City and a large outbreak of more than 100 cases near Havana, Cuba. Factors leading to local and global spread were investigated by layering transportation, geographic, climatic, economic, and demographic information into a large phylogenetic data set of Disease X viruses (panel d). Analyses indicated that virus dispersal from Miami was more likely to occur to large cities that were either: (1) in close driving proximity; or (2) connected by direct flights with high travel volumes. Once in a new city, the success of virus transmission was correlated with low economic status and high population density. This raised concerns about Disease X outbreaks emerging in low-income and densely populated countries within the Caribbean and Central America. The WHO used this information to implement comprehensive surveillance and response efforts in at-risk nations.

Transmission chain tracking

Beyond the initial characterization of an outbreak, virus genome sequencing offers enormous potential for determining transmission chains to understand networks of ‘who-infected-whom’. The tracking of transmission chains has long been a standard part of public health responses to outbreaks, providing critical information that can be used to interrupt virus spread and reduce the magnitude of an outbreak. This work has traditionally been performed using interview-based contact tracing, which is labour intensive and limited by the availability and openness of patients for interviews. This approach is particularly challenging during large outbreaks characterized by large numbers of co-occurring transmission chains.

Virus genomic-based approaches can provide much more in-depth information compared to traditional non-sequencing based approaches, as the branching patterns of phylogenetic trees approximately correspond to transmission from one case to the next (Fig. 1). Virus genome sequences, for example, were used to

**Box 1 | Outbreak of Disease X: a hypothetical scenario (continued)**
Box 2 | Molecular technologies for detecting and tracking outbreaks

Traditional methods. The methods traditionally used to diagnose infectious disease agents in patients are developed to detect either antigens (for example, ELISAs and lateral flow assays), or nucleic acids (for example, PCR) derived from the pathogen. These assays are typically designed to recognize either single (for example, Ebola virus) or closely related (for example, Filoviridae) pathogens. Versions of such assays may also be combined in a multiplexed fashion to detect a small number of different pathogens (for example, haemorrhagic fever viruses). While most laboratories are capable of running these assays, they are often not available for uncommon or novel pathogens, and running multiple rounds of testing can take weeks. They also require a priori knowledge of putative pathogens and cannot typically be used to detect outbreaks that are caused by novel, highly divergent, understudied or rare pathogens.

Deployable solutions. Over the last several years, robust and deployable solutions have been developed for pathogen detection that do not require the maintenance of a cold chain, which can be difficult or impossible under many outbreak conditions. Simple-to-use, point-of-care rapid diagnostic tests have the potential to transform early outbreak detection. For example, the ReEBOV antigen rapid test for Ebola virus infection developed during the recent epidemic could be deployed throughout sub-Saharan Africa to help detect new outbreaks. Simple nucleic acid assays, such as loop-activated isothermal amplification (LAMP) developed for Zika virus, H5N1 avian influenza virus and SARS coronavirus, have eliminated the need for thermal cycling and most power requirements. New and creative advances in microfluidics, nanowire arrays and field-effect biosensors are also helping to reduce the barriers to efficient and rapid diagnostics, while increasing sensitivity and specificity of detection. Of particular interest for deployment in resource-limited settings are paper-based engineered gene circuits, such as sensors designed for strain-specific Ebola virus detection. They are stable for long-term storage at room temperature and are activated by rehydration, and thus can be used in remote environments. Very recently, highly sensitive and deployable CRISPR-based diagnostics have also been developed that utilize CRISPR–Cas13/12a to detect pathogen-derived nucleic acids. Similar to the traditional methods described above, all of these tools require a priori knowledge of probable causal pathogens and the availability of antibodies, genome sequences or other pathogen characteristics.

Sequencing-based methods. Untargeted metagenomic sequencing provides a potential one-step solution for outbreak pathogen detection of both known and novel pathogens, and may be able to replace the need for multiple individual pathogen assays. The main advantage of metagenomic sequencing is that it does not require a priori knowledge of the pathogen, but comes at the expense of specialized equipment, increased costs and bioinformatic complexity. Although high backgrounds of host nucleic acid and/or low pathogen titres in clinical samples can make pathogen detection difficult, host gene depletion and pathogen enrichment methods can help alleviate these issues. After the first outbreak, pathogen genome sequence has been obtained, targeted approaches using next-generation sequencing can also be developed. This was the case for both of the recent Zika and Ebola epidemics, where cheaper and faster amplicon-based approaches were rapidly developed and deployed to track both of the epidemics. The most common platforms used for these purposes are those developed by Illumina (for example, MiSeq and HiSeq), because they have high accuracy and throughput, but they also have high costs and relatively short read lengths (up to 300 base pairs). Cheaper portable devices, such as the miniaturized Oxford Nanopore MinION, can help to produce data in close to real time directly in-country and under austere conditions. This is a significant advancement because, along with open data sharing, rapid diagnostics and sequencing, such devices help promote a comprehensive and collaborative response network.

Reconstruct the spread of foot-and-mouth disease virus in the United Kingdom, including the identification of superspreader events. Genomic data also played a critical role in understanding flare-ups during the West African Ebola outbreak, where phylogenetic analyses showed that most of the flare-ups were linked to persistently infected Ebola survivors, thereby demonstrating sexual transmission of the virus. None of these insights would have been possible without virus genomic data.

The utility of virus genomic data for the inference of transmission chains is dependent on several factors, including: (1) the evolutionary rate of the virus; (2) the length of time between the infections of interest; and (3) the proportion of sampled cases; which together determine the resolution of the genetic signal. Although RNA viruses exhibit remarkably high evolutionary rates, their small genome sizes and short epidemiological generation times often result in, on average, less than one substitution per transmission event (Fig. 2b). Hence, virus genomics alone often cannot be expected to perfectly reconstruct transmission chains at the level of individual infections. Combined with epidemiological data, however, virus genomics provides a powerful tool for restricting the number of possible transmission scenarios and for supporting novel modes of transmission in addition, most phylogenetics-based transmission chain analyses have been performed using virus consensus sequences (that is, a single genome per sample/patient that represents the average of the virus population), which may limit resolution. However, as virus infections exhibit diverse intra-host populations (containing intra-host single nucleotide variants (iSNVs)), newer methods incorporating viral iSNVs may greatly increase the resolution of transmission chain analyses so long as multiple variants are transmitted between hosts.

Outbreak mapping

As described in the previous sections, genomic epidemiology can be used to detect an outbreak, show its origin and elucidate transmission patterns. Evolutionary inferences from virus genomes, unlike non-sequencing based methods, can also be used to dissect the spatial structure and dynamics of spread, as well as to assess how an epidemic may unfold through time and space.

Uncovering the spatial patterns of virus spread during outbreaks is a key objective that has been transformed by genomic epidemiology. Reconstructing a detailed spatial history of virus spread from the origin of an outbreak is generally a task for phylogeographic methods, which provide location estimates for every ancestral node in a virus phylogeny using simple stochastic (or ‘random walk’) models. Phylogenetic analyses, for example, were used to show how Ebola virus spread across West Africa during the 2013–2016 epidemic (Fig. 3). Importantly, virus genome sampling with strong spatiotemporal coverage allowed for the dissection of the entire epidemic into a metapopulation of short- and long-lived transmission chains. Similar analyses were also used to show that multiple introductions were responsible for sustaining the 2016 Zika outbreak in Florida. It is important, however, to appreciate
the uncertainty of phylogeographic estimates, and to bear in mind that such analyses may only be capable of elucidating partial pictures of outbreak spread. In addition, sampling biases may severely affect these analyses, although the coalescent and birth–death models mentioned above have been extended to account for aspects of virus population structure, making the analyses more robust to sampling heterogeneity.

Phylogeographic inference methods can also be used to provide insights into the factors driving virus spread (Fig. 3). Such analyses are enabled by the integration of virus genomics with diverse meta-data sets and are critically dependent on the timeliness of data generation and open sharing. These approaches were initially introduced to confirm the key role of human air transportation in the global circulation of influenza viruses, but they have also been useful in untangling complex virus transmission dynamics on smaller scales. To illustrate these methods, in Fig. 3 we show an application of generalized linear modelling to explain Ebola virus migration rates between locations as a function of several potential predictors, to infer virus spread during West African Ebola outbreak (Fig. 3). In this case, geographic distances and population sizes at the location of origin and destination combine into a gravity model of spread, with virus transmission largely occurring within large population centres and geographic spread being more frequent over shorter distances. These phylodynamic studies illustrate the growing importance of data integration for virus genomic analyses, which critically depend on accurate metadata (for example, sampling date and sampling location), as well as other data sources that can capture host mobility and geographic, demographic and epidemiological context.

Inter-epidemic evolution and spread

Once outbreaks have been brought under control or (temporarily) resolved, phylogenetetic analyses can provide insights into evolutionary patterns during inter-epidemic periods by comparing virus genome sequences sampled across different outbreaks. The most fundamental question is whether the virus in question has been able to persist in human populations between outbreaks, so that each new outbreak has arisen from an endemically circulating lineage (for example, dengue virus), or whether they represent independent zoonotic spillover events from an animal reservoir (for example, Ebola virus). With sufficient sampling of viruses from human and reservoir species, this question can be answered using standard phylogenetic analysis. For example, although both dengue virus and yellow fever virus have transmission cycles that involve mosquitoes and humans (urban transmission) or nonhuman primates (sylvatic transmission), phylogenetic analyses have shown that dengue virus is now an entirely endemic urban virus that does not rely on its sylvatic vectors and hosts to seed new epidemics. Most human outbreaks of yellow fever, in contrast, have been shown by virus genomics approaches to represent independent...
emergences of the virus from sylvatic sources, rather than spread via an urban cycle\textsuperscript{45,59}.

Inter-epidemic analyses can also be used to elucidate the nature of virus evolution and spread in reservoir species, which are probably characterized by different evolutionary forces than those seen during human outbreaks\textsuperscript{6,12,70}. For example, although human outbreaks of Ebola have happened relatively frequently since the 1970s, each outbreak starts as an independent spillover of the virus from an animal (probably bat\textsuperscript{8}) reservoir. Hence, the inter-epidemic evolution of Ebola virus occurs in a species other than humans, such that patterns of genetic divergence among the viruses associated with human epidemics can provide insight into viral replication and transmission within reservoir hosts. For example, there have been suggestions that Ebola virus has spread across Africa in a wave-like manner in its reservoir species\textsuperscript{6,11,55,71}; however, phylogenetic analyses incorporating virus genomic data from recent outbreaks are incompatible with this scenario\textsuperscript{6}. Additionally, while Ebola virus normally evolves according to a relatively constant molecular clock\textsuperscript{6,45,75–77}, the phylogenetic branch leading to the viruses sequenced from the small Ebola outbreak that occurred in the Democratic Republic of the Congo in 2014, concurrent with the 2013–2016 epidemic in West Africa, was characterized by a far lower evolutionary rate\textsuperscript{6}. Although the reasons for this reduction in evolutionary tempo are unclear, it is possible that it reflects Ebola virus evolution in a different (unknown) reservoir species that experiences a lower rate of viral replication. Alternatively, this rate disparity may result from the existence of different viral replication states within the same reservoir host, similar to that described during human epidemics, with faster rates observed during continuous human-to-human transmission and slower rates during persistent infections of Ebola survivors\textsuperscript{79}.

**Requirements and challenges in genomic epidemiology**

Virus genomic methods for outbreak investigation and control are powerful additions to more traditional epidemiological approaches but are critically dependent on well-planned and coordinated efforts. The foremost need for genomic epidemiology is timely access to clinical samples and data, which should be built on productive and equitable collaborations with local communities, public health agencies, outbreak responders, local clinics and researchers\textsuperscript{8}. For each clinical sample to be used for virus genomic sequencing, it is essential to obtain a minimal set of metadata related to the infection, including: (1) the date of sample collection and/or onset of symptoms; and (2) the location of sampling. Additional information can greatly increase the utility of genomic epidemiology, including the availability of: (3) travel and contact history; (4) suspected source of infection; and (5) clinical outcome and symptoms. Other factors, including patient history, age, sex and economic status, can also help to reveal risk factors underlying infection and transmission. Within ethical constraints, it is important that communication lines remain open so that researchers undertaking data analysis can return actionable results to the public health community.

Other large-scale data resources are essential for investigating the spatio-temporal history and spread of an outbreak. These include the temporal and spatial distribution of cases, ecological conditions, vector abundance, environmental factors and travel patterns. Integration of these other data sources with virus genomic data may reveal new properties of an outbreak, potentially leading to actionable measures\textsuperscript{55,61,65,75}. Non-genomic data often comes from established networks of collaborations, or from the public domain, highlighting the value of open data and data sharing to outbreak investigations.

An important benefit of genomic epidemiology is that it can directly compare and jointly analyse virus genome sequences obtained during an epidemic, even if those sequences were generated by different laboratories. Consequently, there is an urgent need to make genomic and epidemiological data and analysis tools publicly available during ongoing epidemics\textsuperscript{81}. This movement is supported by the World Health Organization (WHO), which has called for data pertaining to public health emergencies to be disseminated openly and immediately following generation, and not withheld until the acceptance or publication of a corresponding scientific paper\textsuperscript{82}. More recently, the WHO has outlined the current and future benefits of virus genome data sharing during outbreaks\textsuperscript{83}. Combined with an acceleration of making manuscripts available via preprint servers such as arXiv and bioRxiv, especially during...
outbreaks, there has been a shift towards scientists storing their data and source code on depositories such as GitHub (https://www.github.com), Synapse (https://www.synapse.org) and Data Dryad (https://www.datadryad.org), in close to real-time for others to use. Furthermore, extensive online communities and forums such as Twitter (https://www.twitter.com), Virological (http://virological.org), Flutrackers (https://www.flutrackers.com), ProMED (https://www.promedmail.org), Nextstrain (https://www.nextstrain.org), HealthMap (https://www.healthmap.org) and Microreact (https://www.microreact.org) allow rapid dissemination of unpublished results and analyses. In our experience, not only does the process of open science promote new collaborations and lead to more accurate scientific insights into outbreak research, but it helps in getting relevant information rapidly into the hands of decision makers. Despite these advances, however, the speed, nature and extent of virus genome data sharing is inconsistent, sometimes resulting in confusion over what is, or should be, best practice.

Future perspective
Genomic epidemiology promises much to the study and control of infectious disease outbreaks, particularly if viral genomes can be acquired and analysed in real-time. The accumulated set of these data—together with the rapid development of sophisticated software packages (http://virological.org/c/software)—will provide a valuable resolve for the mitigation and control of future outbreaks. Ultimately, with sufficient genome sequences from individual viral genera and/or families, it may be possible to categorize viruses by their phylogenetic patterns and utilize this information in epidemic preparedness. For example, as well as considering obvious biological features of viruses such as their genome structure and mode of transmission, it may be possible to group viruses according to a series of evolutionary variables such as rate of evolutionary change, extent of antigenic evolution, frequency of recombination, pattern of geographic spread and population dynamics. This information may then help forecast the evolutionary behaviour of any virus, should it re-emerge in human populations, and assist in the selection of future vaccine strains. This information will also help counter the alarmist claims that emerging viruses will evolve novel phenotypes, such as airborne transmission in the case of Ebola virus, that often accompany any major disease outbreak. It is clear, however, that a more fundamental understanding of the genetic and ecological barriers of virus spillover into human populations is needed to better identify risk factors for disease emergence. Long-term capacity building, partnerships with local communities, and commitments to long-term investments on these fronts will go a long way towards better enabling the global community to effectively and rapidly deal with future emerging outbreaks.

Received: 26 May 2018; Accepted: 19 October 2018; Published online: 13 December 2018

References
1. Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967–1976 (2003).
2. Ksiazek, T. G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953–1966 (2003).
3. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E. & Fouchier, R. A. M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814–1820 (2012).
4. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360, 2605–2615 (2009).
5. Smith, G. J. D. et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459, 1122–1125 (2009).
6. Holmes, E. C., Dudas, G., Rambaut, A. & Andersen, K. G. The evolution of Ebola virus: insights from the 2013–2016 epidemic. *Nature* 538, 305–313 (2016).
7. Grubaugh, N. D., Faria, N. R., Andersen, K. G. & Pybus, O. G. Genomic insights into Zika virus emergence and spread. *Cell* 172, 1160–1162 (2018).
8. Morse, S. S. in *Plagues and Politics* (ed. Mullan, F.) 8–26 (Palgrave Macmillan, London, 2001).
9. Wolle, N. D., Dunavan, C. P. & Diamond, J. Origins of major human infectious diseases. *Nature* 447, 279–283 (2007).
10. Holmes, E. C., Rambaut, A. & Andersen, K. G. Pandemics: spend on surveillance, not prediction. *Nature* 558, 180–182 (2018).
11. Holland, J. et al. Rapid evolution of RNA genomes. *Science* 215, 1577–1585 (1982).
12. Duffy, S., Shackleton, L. A. & Holmes, E. C. Rates of evolutionary change in viruses: patterns and determinants. *Nat. Rev. Genet.* 9, 267–276 (2008).
13. Kiko, H., Niggemann, E. & Rüger, W. Physical mapping of the restriction fragments obtained from bacteriophage T4 dC DNA with the restriction endonucleases Smal, KpnI and BglII. *Mol. Gen. Genet.* 172, 303–312 (1979).
14. Chungue, E., Deubel, V., Cassar, O., Laille, M. & Martin, P. M. Molecular epidemiology of dengue 3 viruses and genetic relatedness among dengue 3 strains isolated from patients with mild or severe form of dengue fever in French Polynesia. *J. Gen. Virol.* 74, 2765–2770 (1993).
15. Lanciotti, R. S. et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. *Science* 286, 284–287 (2000).
16. Kinnunen, L., Pöyry, T. & Hovi, T. Generation of virus genetic lineages during an outbreak of poliomyelitis. *J. Gen. Virol.* 72, 2483–2489 (1991).
17. McNearney, T. et al. Limited sequence heterogeneity among biologically distinct human immunodeficiency virus type 1 isolates from individuals involved in a clustered infectious outbreak. *Proc. Natl Acad. Sci. USA* 87, 1917–1921 (1990).
18. Nichol, T. S. et al. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. *Science* 262, 914–917 (1993).
19. Ou, C. Y. et al. Molecular epidemiology of HIV transmission in a dental practice. *Science* 256, 1165–1171 (1992).
20. Power, J. P. et al. Molecular epidemiological analysis of a new hemorrhagic fever-associated arenavirus from southern Africa. *PLoS Pathog.* 5, e1000455 (2009).
21. Gardy, J. L. & Loman, N. J. Towards a genomics-informed, real-time, global pathogen surveillance system. *Nat. Rev. Genet.* 19, 9–20 (2018).
22. Salazar-Brago, J., Rueda, L. A. & Yates, T. L. Mammalian reservoirs of arenaviruses. *Curr. Top. Microbiol. Immunol.* 262, 25–63 (2002).
23. dos Reis, M., Donoghue, P. C. J. & Yang, Z. Bayesian molecular clock dating of species divergences in the genomic era. *Nat. Rev. Genet.* 17, 71–80 (2016).
24. Rambaut, A. & Holmes, E. The early molecular epidemiology of the swine-origin A/H1N1 influenza pandemic. *PLoS Curr.* 1, RRN1003 (2009).
25. Korber, B. Timing the ancestor of the HIV-1 pandemic strains. *Science* 288, 1789–1796 (2000).
26. Cotton, M. et al. Full-genome deep sequencing and phylogenetic analysis of novel human betacoronaviruses. *Emerg. Infect. Dis.* 19, 736–428 (2013).
27. Rambaut, A. Estimating the rate of molecular evolution: incorporating non-contemporaneous sequences into maximum likelihood phylogenies. *Bioinformatics* 16, 395–399 (2000).
28. Drummond, A., Pybus, O. G. & Rambaut, A. Inference of viral evolutionary rates from molecular sequences. *Adv. Parasitol.* 54, 331–358 (2003).
29. Drummond, A. J., Nicholls, G. K., Rodrigo, A. G. & Solomon, W. Estimating mutation parameters, population history and genealogy simultaneously from temporally spaced sequence data. *Genetics* 161, 1307–1320 (2002).
30. Möller, S., du Plessis, L. & Ladsl, T. Impact of the tree prior on estimating clock rates during epidemic outbreaks. *Nat. Natl. Sci. USA* 115, 4200–4205 (2018).
31. Duchêne, S., Holmes, E. C. & Ho, S. Y. Y. Analyses of evolutionary dynamics in viruses are hindered by a time-dependent bias in rate estimation. *Proe. Bio. Sci.* 281, 20140732 (2014).
32. Hall, M. D., Woolhouse, M. E. J. & Rambaut, A. Using genomic data to reconstruct transmission trees during disease outbreaks. *Rev. Sci. Tech.* 35, 287–296 (2016).
33. Fraser, C. et al. Pandemic potential of a strain of influenza A (H1N1): early findings. *Science* 324, 1557–1561 (2009).
67. Lemey, P. et al. Unifying viral genetics and human transportation data to predict the global transmission dynamics of human influenza H3N2. PLoS Pathog. 10, e1003932 (2014).

68. Wang, W. et al. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J. Virol. 74, 3227–3234 (2000).

69. Cardoso, J. & de, C. et al. Yellow fever virus in Haemagogus leucocelaenus and Aedes serratus mosquitoes, southern Brazil, 2008. Emerg. Infect. Dis. 16, 1918–1924 (2010).

70. Faria, N. R. et al. Genomic and epidemiological monitoring of yellow fever virus transmission potential. Science 361, 894–899 (2018).

71. Dietzel, E., Schudt, G., Krähling, V., Matrosovich, M. & Becker, S. Establishment and cryptic transmission of Zika virus in Brazil and the Americas. Nature 542, 436–439 (2016).

72. Hattersley, S. M., Greenman, J. & Haswell, S. J. The application of microfluidic devices for viral diagnosis in developing countries. Methods Mol. Biol. 949, 385–393 (2013).

73. Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza viruses. Nature 530, 1097–1104 (2016).

74. Luksza, M. & Lässig, M. A predictive fitness model for influenza. Science 356, 438–442 (2017).

75. Osterholm, M. T. et al. Active Ebola virus replication and heterogeneous viral replication potential. Cell 151, 1097–1106 (2012).

76. Sabir, J. S. M. et al. Development and evaluation of a novel loop-mediated isothermal amplification method for rapid detection of severe acute respiratory syndrome coronavirus. J. Clin. Microbiol. 42, 1956–1961 (2004).

77. Carroll, S. A. et al. Molecular evolution of viruses of the family Filoviridae based on 97 concatenated gene sequences. Science 353, 658 (2016).

78. Leroy, E. et al. Fruit bats as reservoirs of Ebola virus. Nature 438, 575–576 (2005).

79. Walsh, P. D., Biek, R. & Real, L. A. Wave-like spread of Ebola Zaire. PLoS Biol. 3, e371 (2005).

80. Rambaut, A. et al. Comment on ‘Mutation rate and genotype variation of non-coding regions of Ebola virus from the 2014 Sierra Leone outbreak’. Nat. Commun. 8, 14751 (2017).

81. Yozwiak, N. L., Schaffner, S. F. & Sabeti, P. C. Data sharing: make outbreak science a reality. Sci. Adv. 2, e1600378 (2016).

82. WHO. Policy statement on data sharing by WHO in the context of public health emergencies (as of 13 April 2016).

83. Luksza, M. & Lässig, M. A predictive fitness model for influenza. Science 356, 438–442 (2017).

84. Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza viruses. Nature 530, 1097–1104 (2016).

85. Matranga, C. B. et al. Enhanced methods for unbiased deep sequencing of Zika and other virus genomes directly from clinical samples. Nat. Protoc. 12, 1261–1276 (2017).

86. Osterholm, M. T. et al. Reduced evolutionary rate in reemerged Ebola virus transmission chains. Sci. Adv. 2, e1600378 (2016).

87. Yozwiak, N. L., Schaffner, S. F. & Sabeti, P. C. Data sharing: make outbreak science a reality. Sci. Adv. 2, e1600378 (2016).

88. Neher, R. A., Bedford, T., Daniels, R. S., Russell, C. A. & Shraiman, B. I. Novel graphene-based biosensor for rapid detection of Ebola antigen. Sci. Rep. 7, 10974 (2017).

89. Afshari, S. et al. Novel graphene-based biosensor for rapid detection of Zika virus infection. Biosens. Bioelectron. 100, 85–88 (2018).

90. Neher, R. A., Bedford, T., Daniels, R. S., Russell, C. A. & Shraiman, B. I. Novel graphene-based biosensor for rapid detection of Ebola antigen. Sci. Rep. 7, 10974 (2017).

91. Afshari, S. et al. Novel graphene-based biosensor for rapid detection of Zika virus infection. Biosens. Bioelectron. 100, 85–88 (2018).

92. Pardee, K. et al. Paper-based synthetic gene networks. Cell 159, 940–954 (2014).

93. Whitmer, S. L. M. et al. Ebola virus replication and heterogeneous viral replication potential. Cell 151, 1097–1106 (2012).

94. Osterholm, M. T. et al. Reduced evolutionary rate in reemerged Ebola virus transmission chains. Sci. Adv. 2, e1600378 (2016).

95. Gootenberg, J. S. et al. Novel acid detection with CRISPR-Cas13a/C2c2. Science 356, 438–442 (2017).

96. Osterholm, M. et al. Field deployable viral diagnostics using CRISPR-Cas13. Science 360, 444–448 (2018).

97. Gootenberg, J. S. et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 360, 439–444 (2018).

98. Gootenberg, J. S. et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 360, 439–444 (2018).

99. Gootenberg, J. S. et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 360, 439–444 (2018).

100. Broadhurst, M. J. et al. ReEBOV antigen rapid test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study. Lancet 386, 867–874 (2015).

101. Chotivan, N. et al. Rapid and specific detection of Asian- and African-lineage Zika viruses. Sci. Transl. Med. 9, eaag0538 (2017).

102. Imai, M. et al. Development of H5-RT-LAMP (loop-mediated isothermal amplification) system for rapid diagnosis of H5 avian influenza virus infection. Vaccine 24, 6679–6682 (2006).

103. Hong, T. C. T. et al. Development and evaluation of a novel loop-mediated isothermal amplification method for rapid detection of severe acute respiratory syndrome coronavirus. J. Clin. Microbiol. 42, 1956–1961 (2004).

104. Hong, T. C. T. et al. Development and evaluation of a novel loop-mediated isothermal amplification method for rapid detection of severe acute respiratory syndrome coronavirus. J. Clin. Microbiol. 42, 1956–1961 (2004).

105. Chotivan, N. et al. Rapid and specific detection of Asian- and African-lineage Zika viruses. Sci. Transl. Med. 9, eaag0538 (2017).

106. Imai, M. et al. Development of H5-RT-LAMP (loop-mediated isothermal amplification) system for rapid diagnosis of H5 avian influenza virus infection. Vaccine 24, 6679–6682 (2006).

107. Afsahi, S. et al. Novel graphene-based biosensor for rapid detection of Zika virus infection. Biosens. Bioelectron. 100, 85–88 (2018).

108. Pardee, K. et al. Paper-based synthetic gene networks. Cell 159, 940–954 (2014).

109. Gootenberg, J. S. et al. Novel acid detection with CRISPR-Cas13a/C2c2. Science 356, 438–442 (2017).

110. Osterholm, M. T. et al. Reduced evolutionary rate in reemerged Ebola virus transmission chains. Sci. Adv. 2, e1600378 (2016).

111. Gootenberg, J. S. et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 360, 439–444 (2018).

112. Chotivan, N. et al. Rapid and specific detection of Asian- and African-lineage Zika viruses. Sci. Transl. Med. 9, eaag0538 (2017).

113. Imai, M. et al. Development of H5-RT-LAMP (loop-mediated isothermal amplification) system for rapid diagnosis of H5 avian influenza virus infection. Vaccine 24, 6679–6682 (2006).